CIBC Private Wealth Group
ACAD icon

CIBC Private Wealth Group’s Acadia Pharmaceuticals ACAD Stock Holding History

CIBC Private Wealth Group’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$801 Sell
30
-8
-21% -$191 ﹤0.01% 2958
2025
Q3 		$811 Buy
+38
New +$899 ﹤0.01% 2840
2017
Q4 		– Sell
-15,195
Closed -$572K – 1916
2017
Q3 		$572K Buy
+15,195
New +$494K ﹤0.01% 750

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

CIBC Private Wealth Group's ACAD Position: Q4 2025 in Review

CIBC Private Wealth Group reduced its Acadia Pharmaceuticals (ACAD) stake by 21% in Q4 2025, selling an estimated $191 and leaving 30 shares worth $801. The position accounts for ﹤0.01% of the portfolio, ranked #2958.

CIBC Private Wealth Group first reported a position in ACAD in Q3 2017 and has held it in 3 quarters since. The position peaked at $572K in Q3 2017. 336 funds tracked by Wall St. Rank hold ACAD as of Q4 2025.

  • CIBC Private Wealth Group held 30 shares of Acadia Pharmaceuticals worth $801 as of Q4 2025.
  • CIBC Private Wealth Group sold 8 Acadia Pharmaceuticals shares in Q4 2025, an estimated $191.
  • Acadia Pharmaceuticals made up ﹤0.01% of CIBC Private Wealth Group's portfolio in Q4 2025, its #2958 holding.
  • CIBC Private Wealth Group first reported a position in Acadia Pharmaceuticals in Q3 2017 and has held it in 3 quarters since.
  • CIBC Private Wealth Group's Acadia Pharmaceuticals position peaked at $572K in Q3 2017.
  • 336 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q4 2025.

Based on CIBC Private Wealth Group's 13F filing for Q4 2025, filed 12 Feb 2026.